REGENXBIO (RGNX) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
REGENXBIO (RGNX) has outperformed Rezolute (RZLT) over the past year, losing 33.8% versus a loss of 46.8%. Over five years, RZLT leads with a -30.2% price change compared with -77.5% for RGNX. REGENXBIO is the larger company by market cap ($532.7 million vs $471.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGNX | RZLT |
|---|---|---|
| Share price | $8.07 | $4.87 |
| Market cap | $532.73M | $471.04M |
| 1-day change | -0.25% | +4.96% |
| YTD return | -43.82% | +96.61% |
| 1-year return | -33.80% | -46.79% |
| 5-year return | -77.50% | -30.23% |
| EPS (TTM) | $-3.78 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.19 | $11.46 |
| 52-week low | $5.46 | $1.07 |
| Distance from 52-week high | -50.15% | -57.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +192.19% | +101.23% |
| Average volume | 1.53M | 1.50M |
| Shares outstanding | 66.01M | 96.72M |
| Employees | 371 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RGNX has outperformed RZLT by 13.0 percentage points over the past year.
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
RGNX vs RZLT FAQ
Which is bigger, REGENXBIO or Rezolute?
REGENXBIO (RGNX) is larger, with a market capitalization of $532.73M compared with $471.04M for Rezolute (RZLT).
Which stock has performed better over the past year, RGNX or RZLT?
RGNX returned -33.80% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are REGENXBIO and Rezolute in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO and Biotechnology: Pharmaceutical Preparations for Rezolute.